New Clinical Data Backs Subcutaneous Leqembi for Alzheimer’s

The clinical evidence, shared by BioArctic AB and its partner Eisai, demonstrates that a once-weekly 500 mg subcutaneous dose achieves drug exposure levels bioequivalent to the standard intravenous regimen. Because efficacy and safety outcomes are driven by drug exposure rather than the delivery method, researchers noted that the subcutaneous route offers a viable, at-home alternative to hospital-based infusions.

Clinical trials and real-world observations bolster this shift in delivery. At the Alzheimer’s Research and Treatment Center, patients using the subcutaneous autoinjector showed a slower rate of cognitive decline over 36 months compared to a matched natural history cohort. Furthermore, patient and caregiver surveys indicated high satisfaction rates, with many reporting greater convenience and flexibility in their treatment schedules. The safety profile, including the incidence of ARIA-E, remained consistent with intravenous therapy, while the rate of anti-drug antibodies was minimal at 1.4%.